Quotient Sciences Miami Inc — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$1,525,690	68
2024	Research	$4,120,425	92
2023	Research	$8,194,134	122
2022	Research	$744,757	6
2021	Research	$999,031	6
2020	Research	$2,431,723	26
2019	Research	$2,261,912	17

Breakdown

Who paid Research payments · program years 2019–2025

Gilead Sciences, Inc. $13,463,053 279 payments
Pfizer Inc. $2,792,731 29 payments
Baxter Healthcare $2,480,615 15 payments
H. Lundbeck A S $1,339,287 10 payments
Genentech, Inc. $201,987 4 payments

Studies the money was for Research payments · program years 2019–2025

Bioequivalence Study Assessing a Single Dose of Iron Sucrose Injection -Baxter- or a Single Dose of Venofer Injection in Healthy Adult Subjects $2,480,615 15 payments
Safety and Tolerability of Lu AG06474 in Healthy Young Men $1,121,953 9 payments
A Phase 1 Openlabel Study in Healthy Participants to Investigate the Pharmacokinetics of Pf06700841 Following Single Oral Administration of Modified Release Formulations Under Fed and Fasted Conditions in Part A and A Randomized Doubleblind Sponsoropen Placebo Controlled Study to Evaluate Safety Tolerability and Pharmacokinetics of Pf06700841 Following Multiple Oral Administration of Modified Release Formulation Under Fasted Condition in Part B $806,357 5 payments
A Phase 1 Randomized Open Label Fixed Sequence Study to Estimate the Effect of Pf06826647 on the Pharmacokinetics of Oral Contraceptive Steroids and to Estimate the Effect of Oral Contraceptive Steroids on Pharmacokinetics of Pf06826647 in Healthy Female Participants $682,821 10 payments
A Phase 1 Randomized Open Label 2 Way Crossover Study to Demonstrate A Lack of An Effect of Multiple Dose PF 06651600 on the Pharmacokinetics of Single Dose Oral Contraceptive Steroids in Healthy Female Participants $613,528 7 payments
A Phase 1 Randomized Open Label 2Way Crossover Study to Estimate the Effect of Multiple Dose Pf06700841 on the Pharmacokinetics of Single Dose Oral Contraceptive Steroids in Healthy Female Participants $513,384 4 payments
A Phase 1 Study in Healthy Participants to Evaluate the Safety, Tolerability and Pharmacokinetics of Subcutaneous and Intramuscular Lenacapavir $357,803 1 payment
A Phase 1 Study in Healthy Participants to Evaluate the Safety, Tolerability and Pharmacokinetics of Subcutaneous and Intramuscular Lenacapavir $329,951 1 payment
A Phase 1 Study in Healthy Participants to Evaluate the Safety, Tolerability and Pharmacokinetics of Subcutaneous and Intramuscular Lenacapavir $329,951 1 payment
A Phase 1 Study in Healthy Participants to Evaluate the Safety, Tolerability and Pharmacokinetics of Subcutaneous and Intramuscular Lenacapavir $329,951 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.